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Objective: Assessments of endothelial cell function with acetylcholine have typically
used systemic, regional intra-arterial, or iontophoretic delivery of drug. Each of these
techniques induces systemic and/or local changes that compromise their safety or effec-
tiveness. Using translucent drug preparations applied under laser Doppler flowmetry
(LDF)† probes, we tested whether local vasodilation can be induced with non-ion-
tophoretic transdermal delivery of acetylcholine and how such dilation would compare to
the dilation achieved with topical nitroglycerin in healthy volunteers. Methods: Ten sub-
jects without known vascular disease were recruited for LDF monitoring at sites of drug
application for this preliminary investigation. Topical acetylcholine chloride, nitroglycerin,
and placebo were applied via translucent patches to the forehead directly below LDF
probes. Results: LDF readings increased by 406 percent (245 percent to 566 percent)
and 36 percent (26 percent to 46 percent), respectively, at the acetylcholine and placebo
sites (p = .005 by Wilcoxon Signed Rank Test [WSRT] for acetylcholine vs. placebo); and
they increased by 365 percent (179 percent to 550 percent) at the nitroglycerin site (p =
.005 by WSRT for nitroglycerin vs. placebo; p = .6 vs. acetylcholine). Conclusion:
Transdermal delivery of acetylcholine can induce significant local vasodilatory responses
comparable to those achieved with nitroglycerin without requiring iontophoresis. The
means of transdermal delivery and monitoring described herein may constitute a new
minimally invasive way to interrogate the microvasculature and thereby assess the micro-
circulatory changes induced by various disorders and therapeutic interventions.INTRODUCTION
Since the discovery that it acts as an
endothelium-dependent vasodilator [1],
acetylcholine has been used to document
the presence and degree of endothelial cell
dysfunction in a variety of disease states.
In the context of atherosclerotic disease,
intracoronary injection of acetylcholine is
associated with impaired vasodilation or
frank vasoconstriction, leading to the sug-
gestion that it serve as a test for early
detection of coronary artery disease [2-4].
Likewise, the vasodilatory response to
brachial or femoral artery injection of
acetylcholine is compromised in the pres-
ence of coronary artery disease [5] and
hypertension [6]. These approaches have
been used to track attempts to improve
endothelial function in patients with coro-
nary disease [7] and peripheral-arterial
disease [8-12]. However, the need for an
intra-arterial injection has led such tests to
be primarily confined to research settings.
In an effort to avoid the invasive
nature of intra-coronary, intra-femoral, or
intra-brachial injection, investigators have
sought other means of acetylcholine deliv-
ery. Laser Doppler flowmetry (LDF) of
the microvasculature has identified
vasodilation in response to iontophoretic
application of acetylcholine in healthy
subjects and documented that this
response is compromised in patients with
diabetes [13]. While iontophoresis offers a
less invasive method of drug delivery than
intra-arterial injections, it, too, is far from
ideal. In addition to the slight risk of elec-
trical burn from the technique [14], elec-
tric current itself has been shown to be a
potent vasodilator [14], whose effects are
impaired in some vasculopathic subjects
[15]. Even when data are modified to
account for a potential current-induced
effect, the current remains a potential con-
founder in such studies [16]; its effect
varies among specific vehicles and drugs
as well as spatially over the area of drug
delivery [17, 18].
In order to avoid these limitations, we
prepared and tested a means for LDF mon-
itoring of acetylcholine responses via a
translucent, non-iontophoretic, transder-
mal delivery system. In addition, a com-
mercially available translucent patch for
delivery of nitroglycerin (Minitran™
Patch, 3M, Minnesota) was adapted for
LDF monitoring of local changes in
microvascular perfusion without remote or
systemic effects. The primary endpoint of
the present investigation was whether non-
iontophoretic topical application of acetyl-
choline would induce local vasodilation
greater than placebo.We also sought a pre-
liminary understanding of whether the
acetylcholine-induced vasodilation was
comparable to that achieved with nitro-
glycerin.
To our knowledge, this is both the
first report of the use of non-iontophoretic
translucent patches for continuous LDF
monitoring of drug effects during topical
application and the first published report
of the non-iontophoretic, transdermal
effects of acetylcholine on the microcircu-
lation.
MATERIALS AND METHODS
With Institutional Review Board
(IRB) approval, 10 healthy volunteers
were recruited for LDF measurements of
forehead perfusion at sites of transdermal
application of acetycholine, nitroglycerin,
and placebo. For each session, after
informed consent was obtained, subjects
lay on a bed in a semi-recumbent position
in a temperature-controlled room (22 +
1oC).Athree-lead electrocardiogram and a
non-invasive brachial artery blood pres-
sure cuff were applied. Local forehead
skin oils were decreased by wiping lightly
with an alcohol swab, followed by wet and
dry gauze.
Per agreement with our IRB, the
application of acetylcholine to the highly
vascular forehead in this preliminary
investigation was limited to doses of
acetylcholine that did not exceed 10 per-
cent of that used safely in other clinical
settings. We initially tested 10 percent of
the standard 20 mg dose of an acetylchlo-
line-containing preparation (Miochol-E™,
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New Jersey) that is used to induce pupil-
lary constriction during cataract surgery.
While initial (unpublished) trials by our
investigative team found that a 5 percent
solution (20 mg/0.4 ml) of Miochol-E™
induced a 100 percent to 300 percent
increase in local blood flow after topical
application to the forehead under an LDF
probe, the presence of mannitol in the
Miochol-E™ preparation may have affect-
ed local vascular changes. This prompted
our decision to dissolve pure acetylcholine
chloride powder in water.
To achieve a concentrated solution for
delivery of a dose < 2 mg (< 10 percent of
that in the Miochol-E™), 100-mg acetyl-
choline chloride (Spectrum Chemical,
New Brunswick, New Jersey) powder was
freshly mixed with 0.6 ml high pressure
liquid chromatography (HPLC) grade
water to a final volume of approximately
0.7 ml. Then 0.02 ml of this 143 mg/ml
acetylcholine solution (containing 2.86 mg
of drug) was spread on a double stick clear
disk (diameter: 12.6 mm, area: 124.7
mm2). The study sites were delineated by
placing double-stick discs (3M Health
Care, Neuss, Germany) with an overall
diameter of 38.1 mm and a central hole
diameter of 8.7 mm on the forehead.These
discs served as an adherent base onto
which laser Doppler probes were placed,
as well as to define the area (59.4 mm2) for
drug application. Drug delivery was limit-
ed to the area over the central hole of the
double-stick disc (59.4 mm2), or approxi-
mately one-half of the total drug in solu-
tion. The anticipated dose of 1.43 mg was
< 10 percent of the 20 mg dose used for
intraocular injection and allowed for safe,
unanticipated delivery of a slightly greater
quantity of drug. The dry side of the
acetylcholine patch was adhered to the end
of an LDF probe (PF 5010 with Probe
Model 407, Perimed, Järfälla, Sweden). A
sham drug patch was made in the same
way with 0.02 ml of HPLC-grade water
instead of acetylcholine solution.
For transdermal delivery of nitroglyc-
erin, we used a portion of a commercially
available translucent nitroglycerin patch
(Minitran™ nitroglycerin patch, 3M, St.
Paul, Minnesota) which delivers at a
homogenous rate of 0.03 mg/hr/100 mm2.
A section of a standard 20 cm2 patch
(designed to deliver a clinical dose at a
rate of 0.6 mg/hr) was obtained by using a
standard hole-punch to cut a 6 mm diame-
ter (28.3 mm2 area). The delivery of 0.008
mg/hr from this reduced area was well
within the 10 percent safety limit. The
patch then was placed onto a double-stick
disc and placed over an LDF probe in a
similar manner to the acetylcholine patch.
The three LDF probes with patches
attached were placed on a double-stick
disc at three forehead sites so as to enable
undisturbed monitoring and drug delivery.
LDF monitoring was performed continu-
ously at each site for a maximum of 20
minutes or until a vasodilatory plateau was
maintained for > 3 minutes. Data were col-
lected using Chart for Windows
(ADInstruments, Colorado Springs,
Colorado). All LDF sensors were calibrat-
ed using a motility standard (Perimed,
Sweden) twice during the three-month
study period.
The local microvascular effects of
transdermal acetylcholine and nitroglycerin
were tested in 10 healthy volunteers (seven
males, three females; mean age: 36.1;
range: 19 to 56 years) without known vas-
cular disease.An investigator blinded to the
status of the subject and to the nature of the
study site assessed the laser Doppler tracing
at each study site. Our trials demonstrated
that, within 10 seconds of probe applica-
tion, a steady baseline interval was consis-
tently obtainable and that a progressive
drug-induced rise in flow with both acetyl-
choline and nitroglycerin was noted to
beginnosoonerthan30secondsafterprobe
application. This enabled a 20-second base-
line period to be obtained, without the need
to remove the probe for subsequent drug
application. The drug-induced increase in
flow in the present study was determined
by comparing the mean during the lowest
10-second interval during the baseline peri-
od with the mean during the maximum 10-
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Ifnodistinctriseinbloodflowwasevident,
then the highest 10-second interval that
occurred beyond the first two minutes of
readings was used.
All data are presented as the mean with
95 percent confidence intervals (CI). Since
the primary goal was to test whether the
means of delivery and testing introduced
herein generate and delineate a significant
vasodilatory response compared to placebo,
theprimaryendpointwasthepercentchange
in LDF voltage after transdermal application
of each active drug vs. placebo in the study
population. Data were analyzed with the
Wilcoxon Signed Rank Test (WSRT), using
SPSS for Macintosh (SPSS Inc., Chicago,
Illinois). Power analysis was based on
reports that iontophoretic delivery of acetyl-
choline generated increases in skin blood
flow ranging from 160 percent to 710 per-
cent, depending on concentration of drug
and iontophoretic current [19]. Given these
data and our preliminary trials, we anticipat-
ed at least a 100 percent increase in blood
flow (with a standard deviation of 50 per-
cent) at the sites of active patches vs. a 20
percent difference (with a standard deviation
of10percent)atsitesofplaceboapplication.
In order to identify the difference between
the active and placebo patches with an alpha
of 0.025 (simple Bonferroni correction of p
= .05 given two comparisons) and a beta of
0.8,wecalculatedthatasamplesizeofseven
subjects would be required. For values
< 0.05, the actual value is reported; p values
greater than 0.025 were considered not sig-
nificant. With the realization that our study
design was not powered to assess inter-drug
comparisons, a secondary endpoint was
assessed. The effects of the single dose of
acetylcholine were compared to the single
dose of nitroglycerin in the healthy volun-
teers, with the differences analyzed using
WSRT.
RESULTS
Acetylcholine and nitroglycerin both
induced a marked rise in LDF voltage
within two minutes of drug application in
each subject. This was evident not only
with respect to mean flow, but also with
respect to the amplitude of the pulsation
coincident with each heart beat.
Mean blood flow readings increased by
406percent(245percentto566percent)and36
percent(26percentto46percent),respectively,
at the acetylcholine and placebo sites (p = .005
by WSRT for acetylcholine vs. placebo); and
they increased by 365 percent (179 percent to
550 percent) at the nitroglycerin site
(p = .005 byWSRTnitroglyerin vs. placebo; p
=NSnitroglycerinvs.acetylcholine)(Figure1).
Mean baseline pulse amplitude at the
acetylcholine site was 0.13 V (0.06 to 0.19)
at baseline vs. 0.43 V (0.25 to 0.61) during
drug effect (p = .005 by WSRT). For nitro-
glycerin, baseline pulse amplitude was 0.09
V (0.05 to 0.13) vs. 0.25 V (0.13 to 0.36)
during drug effect (p = .005 by WSRT, p =
NS for nitroglycerin vs. acetylcholine).
Mean placebo pulse amplitude did not
changesignificantlygoingfrom0.17V(0.09
to 0.24) to 0.16 V (0.06 to 0.26) during drug
effect (p = NS by WSRT) (Figure 2).
The lack of significant systemic effect
was suggested by the lack of vasodilation at
the placebo site; mean post-drug and base-
line flow and amplitude values did not
change significantly. The slight increase in
flow at the placebo site seen in Figure 2 is
attributable to our method of comparing the
highest 10 second interval after drug appli-
cation with the lowest 10 second interval at
baseline. LDF readings have some temporal
variation even under baseline conditions, a
feature that would be emphasized by look-
ing at maximal differences.Aclinically triv-
ial drop in mean blood pressure was record-
ed from 81 mmHg (75 to 86) at baseline to
78 mmHg (73 to 83) after drug absorption
(p = .03 by WSRT). There was no signifi-
cant change in heart rate: 1.00 Hz (0.90 to
1.11) at baseline vs. 1.04 Hz (0.94 to 1.15)
after drug absorption (p = NS).
DISCUSSION
We have demonstrated that microvas-
cular dilation comparable to that achieved
with iontophoretic delivery [13, 20] can be
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choline and nitroglycerin and that such
effects easily can be monitored via LDF
directly over a translucent delivery vehi-
cle. The local vasodilatory effect of trans-
dermal nitroglycerin has long been appre-
ciated; to the best of our knowledge, a
comparable response to non-iontophoretic
transdermal acetylcholine has not been
reported. Its rapid breakdown by plasma
cholinesterase makes it well-suited to
transdermal application for local testing of
the microvasculature as well as possible
vasodilatory therapy without significant
systemic effect.
The robust response to non-ion-
tophoretic acetylcholine delivery in the
present study may be attributable, in part,
to our choice of the forehead.
Parasympathetic innervation is more
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Figure 1. Boxplots of percent change in blood flow at sites of nitroglycerin, acetyl-
choline, and placebo patches. The boxes incorporate the data between the 25th and
75th percentiles; the line within the boxes is the median; the whiskers on either side show
the full range of data values to within 1.5 times the interquartile range. Beyond that range,
any outliers would have been shown as individual data points. For both drugs vs. placebo:
p = .005).
Figure 2. Boxplots of percent change in pulse amplitude at sites of nitroglycerin, acetyl-
choline, and placebo patches. (See Figure 1 legend). Both drugs vs. placebo: p = .005.prominent in this central region than in the
vasculature of the periphery [14-18], and
the vasodilatory response to iontophoretic
delivery of acetylcholine has been shown
to decrease in the distal periphery as com-
pared to more proximal sites [21]. Prior
research by our team [22, 23] and others
[24] noted that perfusion in central skin
such as that of the forehead tends to be
maintained in the context of vasoconstric-
tive challenges that cause decreased perfu-
sion in the periphery. It has been suggested
that this may be a consequence of homeo-
static cholinergic mechanisms designed to
preserve organ blood flow [25, 26].
It should be noted that the patch tech-
nique described herein may be prone to the
spatial and temporal variation that charac-
terizes LDF readings in general. The
translucent delivery systems enabled us to
obtain a short baseline reading in the initial
period of drug application, thereby avoid-
ing an impact of spatial variation on base-
line-to-drug comparisons. However, the
technique would be improved by a
delayed-release patch that would allow for
a more prolonged baseline measurement.
With the LDF probes employed in this
study, it has been determined that one to
three arteriolar-capillary networks are typi-
cally interrogated in the approximate 1
mm3 volume of tissue that is monitored
[27]. Spatial variability may be reduced
with a larger LDF probe and local mapping
with a moving probe [28] or a laser
Doppler scanner.
Whether the test described will be use-
ful for microvascular assessments of the
endothelium or for therapeutic induction of
local vasodilation remains to be determined.
With further elaboration, this technique may
constitute a useful and minimally invasive
way to interrogate the microvasculature in
general, including its responses in various
disorders and the microcirculatory changes
induced by therapeutic interventions.
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